256 related articles for article (PubMed ID: 24259252)
1. Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection.
Cassol E; Misra V; Morgello S; Gabuzda D
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1087-97. PubMed ID: 24259252
[TBL] [Abstract][Full Text] [Related]
2. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.
Kamat A; Lyons JL; Misra V; Uno H; Morgello S; Singer EJ; Gabuzda D
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):234-43. PubMed ID: 22569268
[TBL] [Abstract][Full Text] [Related]
3. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection.
Lyons JL; Uno H; Ancuta P; Kamat A; Moore DJ; Singer EJ; Morgello S; Gabuzda D
J Acquir Immune Defic Syndr; 2011 Aug; 57(5):371-9. PubMed ID: 21646912
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda.
Abassi M; Morawski BM; Nakigozi G; Nakasujja N; Kong X; Meya DB; Robertson K; Gray R; Wawer MJ; Sacktor N; Boulware DR
J Neurovirol; 2017 Jun; 23(3):369-375. PubMed ID: 27995575
[TBL] [Abstract][Full Text] [Related]
5. HIV-associated neurocognitive disorder.
Smail RC; Brew BJ
Handb Clin Neurol; 2018; 152():75-97. PubMed ID: 29604986
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment.
Cassol E; Misra V; Dutta A; Morgello S; Gabuzda D
AIDS; 2014 Jul; 28(11):1579-91. PubMed ID: 24752083
[TBL] [Abstract][Full Text] [Related]
7. Plasma CXCL10 correlates with HAND in HIV-infected women.
Burlacu R; Umlauf A; Marcotte TD; Soontornniyomkij B; Diaconu CC; Bulacu-Talnariu A; Temereanca A; Ruta SM; Letendre S; Ene L; Achim CL
J Neurovirol; 2020 Feb; 26(1):23-31. PubMed ID: 31414350
[TBL] [Abstract][Full Text] [Related]
8. Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study.
Vassallo M; Dunais B; Durant J; Carsenti-Dellamonica H; Harvey-Langton A; Cottalorda J; Ticchioni M; Laffon M; Lebrun-Frenay C; Dellamonica P; Pradier C
J Neurovirol; 2013 Aug; 19(4):376-82. PubMed ID: 23846287
[TBL] [Abstract][Full Text] [Related]
9. Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.
Rosenthal J; Tyor W
J Neurovirol; 2019 Oct; 25(5):673-685. PubMed ID: 30868422
[TBL] [Abstract][Full Text] [Related]
10. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy.
Kamat A; Misra V; Cassol E; Ancuta P; Yan Z; Li C; Morgello S; Gabuzda D
PLoS One; 2012; 7(2):e30881. PubMed ID: 22363505
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid immune markers and HIV-associated neurocognitive impairments: A systematic review.
Williams ME; Stein DJ; Joska JA; Naudé PJW
J Neuroimmunol; 2021 Sep; 358():577649. PubMed ID: 34280844
[TBL] [Abstract][Full Text] [Related]
12. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.
Chan P; Brew BJ
Curr HIV/AIDS Rep; 2014 Sep; 11(3):317-24. PubMed ID: 24966139
[TBL] [Abstract][Full Text] [Related]
13. Blood-based inflammation biomarkers of neurocognitive impairment in people living with HIV.
Swanta N; Aryal S; Nejtek V; Shenoy S; Ghorpade A; Borgmann K
J Neurovirol; 2020 Jun; 26(3):358-370. PubMed ID: 32193795
[TBL] [Abstract][Full Text] [Related]
14. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.
Coban H; Robertson K; Smurzynski M; Krishnan S; Wu K; Bosch RJ; Collier AC; Ellis RJ
AIDS; 2017 Jul; 31(11):1565-1571. PubMed ID: 28471765
[TBL] [Abstract][Full Text] [Related]
15. Current understanding of HIV-associated neurocognitive disorders pathogenesis.
Gannon P; Khan MZ; Kolson DL
Curr Opin Neurol; 2011 Jun; 24(3):275-83. PubMed ID: 21467932
[TBL] [Abstract][Full Text] [Related]
16. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.
Sereti I; Krebs SJ; Phanuphak N; Fletcher JL; Slike B; Pinyakorn S; O'Connell RJ; Rupert A; Chomont N; Valcour V; Kim JH; Robb ML; Michael NL; Douek DC; Ananworanich J; Utay NS;
Clin Infect Dis; 2017 Jan; 64(2):124-131. PubMed ID: 27737952
[TBL] [Abstract][Full Text] [Related]
17. HIV-Associated Neurocognitive Impairment in the Modern ART Era: Are We Close to Discovering Reliable Biomarkers in the Setting of Virological Suppression?
Bandera A; Taramasso L; Bozzi G; Muscatello A; Robinson JA; Burdo TH; Gori A
Front Aging Neurosci; 2019; 11():187. PubMed ID: 31427955
[TBL] [Abstract][Full Text] [Related]
18. HIV-associated neurological disorders: a guide to pharmacotherapy.
Tan IL; McArthur JC
CNS Drugs; 2012 Feb; 26(2):123-34. PubMed ID: 22201342
[TBL] [Abstract][Full Text] [Related]
19. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
[TBL] [Abstract][Full Text] [Related]
20. Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence.
Gill AJ; Kolson DL
Curr HIV/AIDS Rep; 2014 Sep; 11(3):325-35. PubMed ID: 24929842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
